China NMPA Inspection - Fujian Hongcheng Biopharmaceutical Co., Ltd. - July 19, 2016

An unannounced inspection conducted by the Fujian Provincial Food and Drug Administration resulted in an inspection report published on July 19, 2016, regarding Fujian Hongcheng Biopharmaceutical Co., Ltd. The inspection revealed that the company's actions did not comply with the relevant requirements of the Good Manufacturing Practice (GMP) for Medical Devices. Specifically, significant deficiencies were identified within its quality management system. While the detailed list of specific violations was referenced in an accompanying table not provided in this document, the findings indicated a failure to adhere to the established regulatory framework for medical device manufacturing. As a direct consequence of these findings, Fujian Hongcheng Biopharmaceutical Co., Ltd. has been formally ordered by the Fujian Provincial Food and Drug Administration to rectify all identified deficiencies within a specified timeframe. This mandatory action underscores the importance of maintaining robust quality management systems to ensure compliance with medical device regulations.